Bristol Boosts ImClone Funding To Accelerate Erbitux Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol will invest an additional “several hundred million dollars” toward Erbitux late-stage clinical trials in brain, breast, bladder, esophageal, gastric and lung cancers.
You may also be interested in...
Bristol’s Proposed ImClone Acquisition May Beckon Potential Suitors
If Bristol-Myers Squibb wins its bid for the remaining 83 percent of stock in Erbitux partner ImClone that it does not already own, the evolving biopharma - which itself has been the subject of takeover rumors - could become a more attractive target for potential suitors
Bristol’s Proposed ImClone Acquisition May Beckon Potential Suitors
If Bristol-Myers Squibb wins its bid for the remaining 83 percent of stock in Erbitux partner ImClone that it does not already own, the evolving biopharma - which itself has been the subject of takeover rumors - could become a more attractive target for potential suitors
Bristol-Myers Squibb Eyes A Jewel To Add To Its String Of Pearls
$4.5 billion cash takeover of ImClone would give BMS 100 percent of North American Erbitux sales that totaled $700 million in the first half.